Rak
0000358654
Donate
Active substances for the treatment of:

Malignant stomach cancer

Name of active substance (medicine) The European Society for Medical Oncology (ESMO). Published scientific research demonstrates that the observance of such scientific community guidelines has a positive impact on patient survival rates. Is it included in
the European standard  of treatment (according to ESMO)?
Access status (National Health Fund reimbursement) Additional information
Tegafur / gimeracil / oteracil The drug in this indication is not refunded No reimbursement Tegafur / gimeracil / oteracil is indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin. EPAR/SmPC
Ramucirumab The drug in this indication is not refunded No reimbursement Ramucirumab in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Ramucirumab monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate. EPAR/SmPC
Trastuzumab The drug in this indication is reimbursed for a narrower group of patients than is apparent from the ESMO guidelines Reimbursement with restrictions Metastatic gastric cancer: Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. Trastuzumab should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used. EPAR/SmPC Drug programme